Cell therapy is an area where AcouSort sees great potential for the company's technology. Initially, AcouSort aims at enabling the automation of cell therapy preparation with its AcouWash technology. In a second step, the ambition is to broaden accessibility to cell therapy treatments by reducing production costs. As part of this journey, AcouSort has entered a collaboration with a global life science company active in the cell therapy field.

The initial aim of the collaboration is to demonstrate how AcouSort's AcouWash technology can be adapted for industrial use and integrated as OEM components in the partnering company's future cell therapy products and instruments. This initial collaboration project generates revenues of EUR 150,000 to AcouSort in 2022. The industry collaboration follows a two-year period where AcouSort has been involved in academic projects with similar ambitions developing cell therapy solutions for clinical use.

 

"Cell therapy is alongside of clinical diagnostics one of AcouSort's focus areas. We have previously successfully collaborated with leading academic partners, and the industry collaboration we now have entered marks the beginning of the next step in our efforts to develop an attractive and scalable cell therapy platform for clinical use. It is all very exciting.", says AcouSort's CEO Torsten Freltoft.

 

This information is such information that AcouSort AB (publ) is obliged to publish in accordance with the EU Market Abuse Regulation. The information was submitted, through the agency of the contact person below, for publication on November 14, 2022, at 8:30 CET.

For further information on AcouSort, please contact:

Torsten Freltoft, CEO
Telephone: +45 2045 0854
E-mail: torsten.freltoft@acousort.com

 

About AcouSort

AcouSort AB (corporate registration number 556824-1037) is an innovative technology company focusing on developing products and solutions for integrated preparation of biological samples. With the help of sound waves, the company's products can separate blood cells, concentrate, purify and stain cells, exosomes and bacteria from biological samples. The technology of the company's products is acoustofluidics, where sound waves and microfluidics enable automated handling of samples in a range of application areas, from research on new biomarkers to the development of new diagnostic systems for near-patient testing - so-called Point-of Care (POC) systems. The company's commercialization strategy is based on the already proven business model of providing separation modules to diagnostic system manufacturers for integrated sample preparation as well as to continue the commercialization of the company's research instruments. With the help of the company's products and development of point-of-care tests, new diagnostic systems and treatments are enabled, addressing some of the most challenging disease areas of our time: cancer, infectious diseases and cardiovascular diseases. AcouSort is listed at Nasdaq First North Growth Market. The company's Certified Adviser is Erik Penser Bank, 08-463 83 00, mail to: certifiedadviser@penser.se Erik Penser Bank AB (publ), Apelbergsgatan 27, Box 7405, 103 91 Stockholm.

https://news.cision.com/acousort/r/acousort-expands-its-cell-therapy-efforts-and-enters-collaboration-with-global-life-science-company,c3666069

https://mb.cision.com/Main/15073/3666069/1667075.pdf

(c) 2022 Cision. All rights reserved., source Press Releases - English